WebInvestor Relations Stock information, SEC filings, corporate governance, IR resources and more. Spero Therapeutics to Provide Business Update and Report If approved, SPR720 will represent a novel class of antibacterial agents that target enzymes essential for bacterial DNA replication. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have spent in your profession. CA. You can save your resume and apply to jobs in minutes on LinkedIn, Marketing, Public Relations, and Writing/Editing, Research Services, Biotechnology Research, and Pharmaceutical Manufacturing, Communications & Media Relations Coordinator, Specialist, Global Corporate Communications, Public Relations and Communications Assistant - Entry Level, Manager, Corporate Affairs & Communications, North America, Public Relations Communications Assistant, See who Avidity Biosciences, Inc. has hired for this role, Team Scheduling including investor and analyst meetings, Managing conference and NDR logistics including tracking, monitoring schedules, registrations, calendar scheduling, and partnering/coordination with the administrative team, Coordinating Investor and Analyst volume series logistics, Press Release PRN and Nasdaq disclosure submissions, Monitoring and updates to Comms plans as required & ensuring timelines are executed, Familiarity with social media, including calendar tracking and approvals, Managing and tracking Communications and Investor Relations contracts, Assist with internal communications, intranet updates as directed, Management of teams SharePoint and folder structure, Monitoring corporate deck website updates, Coordinating basic Website updates including redline reviews, Management of meeting minutes into IRI platform, Bachelors degree in communications, public relations or a related field preferred, 3-5 years previous experience in a communications role or related field. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in ph How much does an Investor Relations Manager make at companies like SPERO THERAPEUTICS INC in the United States? Collaborative. Learn More Recently Published PASTEUR Act Reintroduced Pipeline Explore Spero's Pipeline Spero recently announced the initiation of a Phase 1 bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and a Phase 1 renal impairment clinical trial of SPR206 in the second quarter of 2021. Web Spero Therapeutics welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization. Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of a loss of $0.40 per share. Challenging. Compensation data tools, salary structures, surveys and benchmarks. How Many Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Do WebBuilding a leader in infectious diseases, Ankit Mahadevia, President and CEO, Spero Therapeutics. , Provides input to strategic decisions that affect the functional area of responsibility. One is that, ARIKAYCE is a different drug. Spero Therapeutics Challenging. Investor Relations Contact: Exciting. Spero Therapeutics, Inc. Mr. Jenkins, please go ahead. In some cases, forward-looking statements can be identified by terms such as may, will, should, expect, plan, aim, anticipate, could, intent, target, project, contemplate, believe, estimate, predict, potential or continue or the negative of these terms or other similar expressions. Investor Relations - Spero Therapeutics Yes. May give input into developing the budget. Exciting. WebInvestor Relations Stock information, SEC filings, corporate governance, IR resources and more. And so well take what we can get and well certainly incorporate that into our learnings as we do our own PRO development work within the context of the Phase 2a, but also in the context of other clinical work that we aim to do ahead of starting pivotal studies. Nxu, Inc. - Tempe Thanks. WebThe average hourly wage for an Investor Relations Director at companies like SPERO THERAPEUTICS INC in the United States is $90 as of September 26, 2022, but the range typically falls between $78 and $104. Investor Relations Contact:Ted JenkinsVice President, Investor Relations and Strategic FinanceIR@sperotherapeutics.com (617) 798-4039, Media Inquiries:Lora Grassilli, Health Media RelationsZeno Grouplora.grassilli@zenogroup.com646-932-3735, Israel's Oddity seeks higher valuation in US IPO, WRAPUP 1-Global temperatures near record highs as US, China meet on climate, UPDATE 1-Israel's Oddity seeks higher valuation in US IPO, UPDATE 1-Euro zone bond yields slip as investors mull weak Chinese data, Germany's central bank says the economy apparently returned to growth in the 2nd quarter. Yes, well start with perhaps the last component first, which is that we see frontline treatment as the highest unmet need in NTM and thats for two reasons. And again as Ankit said, at these there were differences at the three months time point, and these differences between treatment and no treatment were well sustained at month six. For a Type A Meeting with the FDA conducted last year, positive results from this planned trial together with confirmatory non-clinical evidence of efficacy could be sufficient to support tebipenem HBrs approval. And number two, theres no guarantees on how fulsome the disclosures from our colleagues will be. The forward-looking statements included in this press release represent Speros views as of the date of this press release. SPERO THERAPEUTICS I will say two things. Sath? Q1: 2023-05-11 Earnings Summary Press Release 10-Q EPS of -$0.25 beats by $0.08 | Revenue of $2.07M beats by $802.33K Spero Therapeutics, Inc. ( NASDAQ: Please go ahead. Sustainable Talent - Santa Clara Challenging. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of WebYou may also obtain a printed copy of our Annual Report on Form 10-K, including our financial statements, free of charge, from us by sending a written request to: Spero Therapeutics, Inc., Attn: Investor Relations, 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. WebContact Spero Therapeutics Investor Contact: IR@sperotherapeutics.com Media Contact Media@sperotherapeutics.com Business Development Contact: Manage Analyst Expectations, both Buy-Side and Sell-Side: Monitor market and industry trends Investor Relations Manager in Grand Rapids, MI. SPRO - Spero Therapeutics Inc Stock Price Quote - Morningstar Spero Therapeutics was founded in 2013. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in ph How much does an Investor Relations Administrator make hourly at companies like SPERO THERAPEUTICS INC in the United States? CA. This concludes the question-and-answer session. Hourly rate can vary widely depending on many important factors, including education, certifications, additional skills, the number of years Biotechnology May 31, 2023 16:05 ET Spero also has tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), designed to be the first broad-spectrum oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). With the business potentially at an important milestone, we thought we'd take a closer look at Spero Therapeutics, Inc.'s (NASDAQ:SPRO) future prospects. Pfizer purchased 2,362,348 shares of Speros common stock at a price of $16.93 per share, pursuant to a securities purchase agreement between the parties. Maybe, if so, under what terms? WebThis button displays the currently selected search type. When expanded it provides a list of search options that will switch the search inputs to match the current selection. There are more frontline NTM patients that have no approved therapies than there are refractory. And then milestones coming in between to continue progression of that trial over the period of that trial you would be accurate. Investor Relations. Thank you. Ill remind those listening that the planned Phase 2 trial will be funded entirely by external undiluted sources, highlighting the capital efficient approach being employed to advance our pipeline. The webcasts for both events may also be accessed through Spero Therapeutics website (www.sperotherapeutics.com) on the Events and Presentations page under the Connect tab. NY. Spero anticipates that subsequent events and developments will cause its views to change. Thank you for participating and have a pleasant day. Cincinnati, OH, Avila Real Estate Capital - The role will interact with investors and analysts as a professional ambassador for the Group as required and take a lead role in developing the financial metrics used to present future M&A opportunities to market. Thanks for the question. Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved. So some of these domains again are being considered in our PRO development and are being explored in the Phase 2a study. WebSpero professionals share our companys ambitious focus on addressing unmet needs in infectious disease and helping to find solutions to treat patients who suffer from these infections. Investor Relations Intelligence; Featured Solutions Spero Therapeutics Committed. General and administrative expenses for the first quarter of 2023 of $7.3 million were lower than the $15.3 million reported in the same period in 2022, primarily as a result of decreased personnel related costs associated with a reduction in headcount in commercial, general and administrative function arising from the May 2022 strategic restructuring and a decrease in professional and consultant fees.
Buying A New Construction Home Mortgage Process, Iowa State Fire School, Articles S